IRAPe, Irisin and IL-34 in Patients With Type 2 Diabetes
Launched by DAMANHOUR UNIVERSITY · Sep 26, 2019
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
Aim: This study aimed to evaluate the role of extracellular part of insulin regulated aminopeptidase (IRAPe), IL-34, Irisin, and Visfatin in the development of insulin resistance in patients with type 2 diabetes mellitus.
Methods: parallel study enrolled 60 non-diabetic control subjects and 60 newly-diagnosed type 2 diabetics, matched for age, body mass index and sex ratio. Anthropometric parameters, blood glucose, fasting plasma insulin, insulin resistance index (HOMA-IR), IL34, Irisin, IRAPe, Visfatin and glycated hemoglobin were assessed.
Conclusion: IL-34 and Visfatin levels were sign...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • newly diagnosed type 2 diabetes and non-diabetic control subjects from 35 to 65 years old were enrolled in this study.
- Exclusion Criteria:
- • individuals with inflammatory diseases, Cushing's syndrome, thyroid disorders, infectious diseases, cancers, hepatic diseases and renal impairment. Subjects on insulin or other medications that could affect glucose metabolism or pro-inflammatory cytokines assessment (Glucocorticoids, beta-Adrenergic agonists, Thiazides, etc.....) were also excluded from study
About Damanhour University
Damanhour University is a prominent academic institution in Egypt, dedicated to advancing healthcare and medical research through innovative clinical trials. With a commitment to improving patient outcomes and fostering scientific discovery, the university collaborates with healthcare professionals and researchers to conduct rigorous studies that address critical health challenges. By leveraging its state-of-the-art facilities and expertise, Damanhour University aims to contribute significantly to the body of medical knowledge and enhance the quality of care provided to diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tanta, El Gharbia, Egypt
Patients applied
Trial Officials
Tarek Mostafa, Ass Prof.
Study Chair
Tanta University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials